Medicine and Dentistry
Pleura Mesothelioma
100%
Biological Marker
58%
Diagnosis
54%
Overall Survival
50%
Cytopathology
50%
Supportive Care
46%
Pemetrexed
42%
Immunohistochemistry
38%
Mesothelioma
33%
Effusion
33%
Endometrium Cytology
33%
Thyroid Gland
33%
Non Small Cell Lung Cancer
33%
Prognostic Factor
33%
Therapy Delay
33%
Cytotechnology
33%
Cancer Treatment
33%
Liquid-Based Cytology
33%
Biopsy
33%
Multivariate Analysis
19%
Asbestos Exposure
18%
Neoplasm
17%
Reproducibility
16%
Kappa Statistics
16%
Image Analysis
16%
Cell Nucleus
16%
Diagnostic Error
16%
Disease Free Survival
16%
Recurrent Disease
16%
Vinorelbine
12%
Sarcomatoid
9%
Diseases
9%
Care Group
9%
BRCA1
8%
Squamous Cell Carcinoma
8%
Kaplan Meier Method
6%
Hazard Ratio
6%
Tissue Microarray
6%
Cancer
6%
Proportional Hazards Model
6%
Medical Record
6%
Pharmacology, Toxicology and Pharmaceutical Science
Pleura Mesothelioma
100%
Chemotherapy
73%
Overall Survival
51%
Neoplasm
46%
Pemetrexed
40%
Non Small Cell Lung Cancer
33%
Occupational Exposure
33%
Mesothelioma
33%
Cisplatin
22%
Biological Marker
20%
Disease
13%
Disease Free Survival
11%
Recurrent Disease
11%
Mesothelin
8%
Comorbidity
6%
Retrospective Study
6%
Squamous Cell Carcinoma
5%
Vinorelbine
5%
Keyphrases
Cytotechnologist
33%
Endometrial Cytology
33%
Cytopathology
33%
Reactive Mesothelial Proliferation
19%
Pleural Fluid
8%
Mesothelin
8%
Nuclear Morphology
6%
Benign or Malignant
6%
Kendall Correlation
5%
L-category
5%
Agreement Rate
5%
Kendall Test
5%
Liquid-based Cytology
5%
ROC Area
5%
